Nadia Harbeck - Department of Gynecology and Obstetrics and Comprehensive Cancer Center, the Ludwig-Maximilians-University

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 88 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Discussion of ABC7 Consensus and German Recommendations

Michael Untch,Nina Ditsch, Peter A Fasching,Steffi Busch,Johannes Ettl,Renate Haidinger,Nadia Harbeck,Christian Jackisch,Diana Lüftner,Lothar Müller,Eugen Ruckhäberle,Eva Schumacher-Wulf,Christoph Thomssen,Rachel Wuerstlein,Volkmar Müller

Geburtshilfe und Frauenheilkundeno. 5 (2024): 431-442

Cited0Views0WOSBibtex

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

Journal of clinical oncology : official journal of the American Society of Clinical Oncologyno. 9 (2024): 987-993

Cited0Views0WOSBibtex

Tailoring Neoadjuvant Systemic Therapy in Breast Cancer: "the Advent of a Personalized Approach"-the Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations

CANCERno. 19 (2024): 3251-3271

Cited0Views0WOSBibtex

INAVO122: A Phase III Study of Maintenance Inavolisib or Placebo Plus Pertuzumab Plus Trastuzumab Following Induction with Pertuzumab Plus Trastuzumab Plus a Taxane in Patients (pts) with PIK3CA-mutated, HER2-positive Advanced Breast Cancer (Her2+abc)

Sandra M. Swain, Carlos H. Barrios, Reva K. Basho,Giuseppe Curigliano,Nadia Harbeck, Chiun-Sheng Huang, Maimah Karmo,Sherene Loi,Sara M. Tolaney,Nicholas C. Turner, Annie Collier, Volkmar Henschel, Aneta Swat, Simon Warburton, Fabiola Amair-Pinedo,Javier Cortes

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

Cited0Views0Bibtex

Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple-Negative Breast Cancer: Updated Event-Free Survival Results from the Phase 3 KEYNOTE-522 Study

Peter Schmid,Javier Cortes,Rebecca Dent,Lajos Pusztai,Heather McArthur,Sherko Kuemmel,Carsten Denkert,Yeon Hee Park,Rina Hui,Nadia Harbeck,Masato Takahashi,Theodoros Foukakis, Marie-Ange Mouret-Reynier, Marta Ferreira, Seock-Ah Im,Fatima Cardoso, Yu Ding,Wilbur Pan,Konstantinos Tryfonidis,Joyce O'Shaughnessy

CANCER RESEARCHno. 9 (2024)

Cited0Views0Bibtex

Baseline (BL) Characteristics and Efficacy Endpoints for Patients (pts) with Node-Negative (N0) HR+/HER2− Early Breast Cancer (EBC): NATALEE Trial

Denise A. Yardley,Michael Untch,Carlos H. Barrios,Aditya Bardia,Kevin Kalinsky,Seock-Ah Im,Stephen K. L. Chia,Alistair E. Ring,Nicholas Patrick McAndrew,Vicente Valero,Manuel Ruiz-Borrego,Rodrigo Fresco, Eleanor Sum,Yogesh Chattar, Sorcha Waters,Nadia Harbeck

Journal of Clinical Oncologyno. 16_suppl (2024): 512-512

Cited0Views0Bibtex

Abstract PS06-06: Analysis of Ctdna for the Detection of Minimal Residual Disease (MRD) Using a Tissue-Free, Multiomic Assay in Patients with Early-Stage Breast Cancer

Wolfgang Janni,Thomas Friedl,Brigitte Rack,Peter A. Fasching,Andreas Hartkopf,Hans Tesch,Ralf Lorenz,Georg Heinrich,Jens-Uwe Blohmer,Tanja Fehm,Volkmar Mueller,Andreas Schneeweiss,Matthias Beckmann,Matthias Ruebner,Nadia Harbeck,Klaus Pantel,Derek Dustin, Mingyang Cai

CANCER RESEARCHno. 9 (2024)

Cited0Views0Bibtex

Impact of Dose Reductions on Adjuvant Abemaciclib Efficacy for Patients with High-Risk Early Breast Cancer: Analyses from the Monarche Study

Matthew P. Goetz,Irfan Cicin,Laura Testa,Sara M. Tolaney,Jens Huober,Valentina Guarneri,Stephen R. D. Johnston,Miguel Martin,Priya Rastogi,Nadia Harbeck,Ashwin Shahir, Ran Wei,Valerie Andre,Hope S. Rugo,Joyce O'Shaughnessy

NPJ BREAST CANCERno. 1 (2024)

Cited0Views0WOSNATUREBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn